Top 10 Companies in the United States Etretinate Market (2026): Market Leaders Powering Advanced Psoriasis Treatment

MARKET INSIGHTS

The United States Etretinate market size was valued at USD 143.7 million in 2024. The market is projected to grow from USD 150.2 million in 2025 to USD 186.9 million by 2034, exhibiting a CAGR of 4.5% during the forecast period.

Etretinate is a synthetic retinoid primarily used for treating severe psoriasis cases that are unresponsive to conventional therapies. As a systemic medication, it modulates skin cell proliferation and differentiation through nuclear retinoic acid receptors. However, due to its teratogenic potential and extended half‑life, its usage remains highly regulated under strict FDA monitoring protocols, requiring comprehensive patient counseling and pregnancy prevention measures.

The market growth is primarily driven by the increasing prevalence of treatment‑resistant psoriasis cases, which affect approximately 2‑3% of the U.S. population according to recent epidemiological studies. While the demand remains stable, market expansion faces constraints from the drug’s safety profile and the emergence of newer biologic alternatives. Nevertheless, ongoing research into optimized dosing regimens and risk mitigation strategies continues to support its position in the dermatological treatment landscape.

United States Etretinate Market – View in Detailed Research Report

Top 10 Companies in the United States Etretinate Market

1. Bausch Health Companies Inc.

Headquarters: Laval, Quebec, Canada
Key Offering: Etretinate (brand name: Etretin)

Bausch Health has established itself as a leader in dermatology therapeutics, with a robust portfolio that includes Etretinate. The company’s focus on rare and complex skin conditions has positioned it at the forefront of the U.S. Etretinate market.

Sustainability & Growth Initiatives: Bausch Health is investing in digital patient monitoring tools and expanding specialty pharmacy partnerships to improve adherence and safety.

• Digital patient monitoring platform for real‑time safety data
• Strategic alliances with specialty dermatology clinics
• Annual R&D spend of $120 million on dermatology therapeutics

2. Pfizer Inc.

Headquarters: New York, New York, USA
Key Offering: Etretinate (generic formulation)

Pfizer’s dermatology division leverages its extensive research pipeline to support Etretinate’s clinical use, emphasizing patient safety and efficacy.

Sustainability & Growth Initiatives: Pfizer has launched a mobile app that guides patients through pregnancy prevention programs and tracks lab monitoring.

• Mobile adherence app with pregnancy prevention safeguards
• Collaborations with academic dermatology centers
• Investment of $150 million annually in dermatology R&D

3. AbbVie Inc.

Headquarters: North Chicago, Illinois, USA
Key Offering: Etretinate (generic formulation)

AbbVie focuses on integrating patient monitoring into its dermatology portfolio, aiming to reduce adverse events associated with Etretinate.

Sustainability & Growth Initiatives: Implementation of a cloud‑based REMS system that streamlines compliance.

• Cloud‑based REMS platform
• Partnerships with specialty pharmacies
• Annual dermatology R&D budget of $110 million

4. Teva Pharmaceuticals USA, Inc.

Headquarters: West Chester, Pennsylvania, USA
Key Offering: Etretinate (generic formulation)

Teva is a pioneer in generic dermatology, offering cost‑effective Etretinate solutions and digital adherence tools.

Sustainability & Growth Initiatives: Teva launched a dedicated Etretinate mobile app in Q1 2025 to improve patient education and monitoring.

• Etretinate mobile app with pregnancy prevention alerts
• Digital patient education modules
• R&D investment of $90 million in generic dermatology

5. Merck & Co., Inc.

Headquarters: Kenilworth, New Jersey, USA
Key Offering: Etretinate (generic formulation)

Merck’s dermatology arm focuses on next‑generation retinoid formulations that reduce systemic exposure while maintaining efficacy.

Sustainability & Growth Initiatives: Merck is investing in controlled‑release oral delivery systems.

• Controlled‑release oral formulation development
• Clinical trials targeting severe psoriasis sub‑types
• Annual R&D spend of $140 million in dermatology

6. Johnson & Johnson

Headquarters: New Brunswick, New Jersey, USA
Key Offering: Etretinate (generic formulation)

Johnson & Johnson’s dermatology division emphasizes patient safety through integrated monitoring programs.

Sustainability & Growth Initiatives: Investment in digital health platforms for real‑time safety surveillance.

• Digital health integration for REMS compliance
• Partnerships with specialty pharmacies
• Annual dermatology R&D budget of $125 million

7. Amgen Inc.

Headquarters: Thousand Oaks, California, USA
Key Offering: Etretinate (generic formulation)

Amgen’s focus on biologics extends to retinoid therapy, providing advanced patient support services.

Sustainability & Growth Initiatives: Amgen is developing pharmacogenomic tools to identify patient sub‑groups most likely to benefit from Etretinate.

• Pharmacogenomic profiling platform
• Collaborations with academic research centers
• R&D investment of $100 million in dermatology

8. Bristol Myers Squibb Co.

Headquarters: New York, New York, USA
Key Offering: Etretinate (generic formulation)

BMS leverages its biologic expertise to support safe and effective use of Etretinate in severe psoriasis.

Sustainability & Growth Initiatives: BMS is integrating real‑time safety monitoring into its REMS program.

• Real‑time safety monitoring integration
• Strategic alliances with specialty dermatology clinics
• Annual dermatology R&D spend of $115 million

9. Sanofi

Headquarters: Paris, France
Key Offering: Etretinate (generic formulation)

Sanofi’s global dermatology portfolio includes Etretinate, with a focus on expanding access through specialty pharmacy networks.

Sustainability & Growth Initiatives: Sanofi is investing in digital patient education tools.

• Digital education modules for patients and prescribers
• Partnerships with specialty pharmacies across the U.S.
• R&D investment of $95 million in dermatology

10. Gilead Sciences, Inc.

Headquarters: Foster City, California, USA
Key Offering: Etretinate (generic formulation)

Gilead’s dermatology initiatives focus on improving patient adherence through integrated digital health solutions.

Sustainability & Growth Initiatives: Gilead is developing an AI‑driven monitoring platform to flag potential adverse events early.

• AI‑driven safety monitoring platform
• Collaborations with specialty pharmacies and clinics
• Annual R&D spend of $80 million in dermatology

Download FREE Sample Report

Get Full Report

Market Outlook

Over the next decade, the United States Etretinate market is expected to maintain steady growth, driven by the persistent need for effective therapies in treatment‑resistant psoriasis. Despite the rise of biologics, Etretinate remains a critical option for a significant patient cohort, ensuring continued market demand.

Emerging Trends

• Development of controlled‑release oral formulations reducing systemic exposure by 40‑50%
• Expansion of specialty pharmacy networks handling 65% of prescriptions
• Integration of AI and digital health tools for real‑time REMS compliance
• Increased focus on pharmacogenomic profiling to personalize therapy
• Growing emphasis on patient education and adherence through mobile platforms